Journey Medical Corporation (NASDAQ:DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults.
The clinical trial also assessed the safety and tolerability of the treatment. DFD-29 is being developed for papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd (NYSE:RDY).
Rosacea is a chronic, relapsing, inflammatory skin condition commonly presenting with symptoms such as deep facial redness, acne-like inflammatory lesions, and spider veins.
The study achieved all primary objectives and noted no significant safety issues.
Treatment with DFD-29 for 16 weeks did not significantly impact the normal microbial flora and did not induce significant bacterial resistance.
Additionally, treatment with DFD-29 did not cause a significant proliferation of opportunistic organisms. The results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance.
The company anticipates topline data from the Phase 3 trials in June, with a New Drug Application filing subsequently expected in the second half of 2023.
Price Action: DERM shares are up 8.98% at $1.82 on the last check Tuesday.
